Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-07-12 |
2024-05 |
0 |
N/A |
N/A |
N/A |
2024-04-09 |
2024-02 |
0 |
-0.06 |
N/A |
N/A |
2024-01-12 |
2023-11 |
0 |
-0.13 |
N/A |
N/A |
2024-01-12 |
2023-11 |
0 |
N/A |
N/A |
N/A |
2023-11-21 |
2023-08 |
-0.17 |
-0.12 |
0.05 |
29.41% |
2023-11-21 |
2023-08 |
-0.17 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-07-20 |
Maxim Group |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2019-12-19 |
BAXTER NICHOLAS W |
Director |
330.00K |
Conversion of Exercise of derivative security |
2015-12-15 |
BHULLAR BALJINDER |
Chief Financial Officer |
155.38K |
Stock Award(Grant) |
2022-10-12 |
BUNKA CHRISTOPHER ANDREW |
Chief Executive Officer |
0.00 |
Stock Award(Grant) |
2024-05-13 |
CARLE VANESSA |
Officer |
2.63K |
Conversion of Exercise of derivative security |
2018-08-30 |
DOCHERTY JOHN MARTIN |
President |
0.00 |
Stock Award(Grant) |
2022-10-13 |
DOWNEY GREGORY |
Chief Financial Officer |
1.95K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Invenomic Capital Management, LP |
766.57K |
559.83K |
0.95% |
2023-06-29 |
Geode Capital Management, LLC |
48.84K |
35.67K |
0.06% |
2023-06-29 |
Vanguard Group Inc |
33.33K |
24.34K |
0.04% |
2023-06-29 |
Susquehanna International Group, LLP |
15.43K |
11.27K |
0.02% |
2023-06-29 |
Renaissance Technologies, LLC |
10.70K |
7.81K |
0.01% |
2023-06-29 |
Tower Research Capital LLC (TRC) |
10.95K |
8.00K |
0.01% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-07-30 |
Northern Lights Fd Tr II-Invenomic Fd |
655.43K |
546.30K |
0.81% |
2023-05-30 |
Fidelity Extended Market Index Fund |
39.10K |
29.04K |
0.05% |
2023-06-29 |
Vanguard Extended Market Index Fund |
33.33K |
24.34K |
0.04% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
5.48K |
4.07K |
0.01% |
Split |
Date |
1 : 30 |
2021-01-12 |